Literature DB >> 22764073

A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design.

Kathrin Stucke1, Meinhard Kieser.   

Abstract

In the three-arm 'gold standard' non-inferiority design, an experimental treatment, an active reference, and a placebo are compared. This design is becoming increasingly popular, and it is, whenever feasible, recommended for use by regulatory guidelines. We provide a general method to calculate the required sample size for clinical trials performed in this design. As special cases, the situations of continuous, binary, and Poisson distributed outcomes are explored. Taking into account the correlation structure of the involved test statistics, the proposed approach leads to considerable savings in sample size as compared with application of ad hoc methods for all three scale levels. Furthermore, optimal sample size allocation ratios are determined that result in markedly smaller total sample sizes as compared with equal assignment. As optimal allocation makes the active treatment groups larger than the placebo group, implementation of the proposed approach is also desirable from an ethical viewpoint.
Copyright © 2012 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2012        PMID: 22764073     DOI: 10.1002/sim.5461

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

2.  Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial.

Authors:  Xiaoyu Liu; Wanqi Yang; Chao Zhang; Heng Wu; Ruize Wang; Qiang Ding; Yan Hu; Yongli Xiong; Shaobai Zhang; Lin Wang
Journal:  Hum Vaccin Immunother       Date:  2021-12-14       Impact factor: 3.452

Review 3.  Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

Authors:  James M S Wason; Lynne Stecher; Adrian P Mander
Journal:  Trials       Date:  2014-09-17       Impact factor: 2.279

4.  Do incentives undermine intrinsic motivation? Increases in intrinsic motivation within an incentive-based intervention for people living with HIV in Tanzania.

Authors:  Nancy L Czaicki; William H Dow; Prosper F Njau; Sandra I McCoy
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.